1-8 of 8
Timothy Burn, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2509.
https://doi.org/10.1182/blood-2019-130458
Published: 2019
Journal Articles

Cell-of-Origin Subtype Prediction of Diffuse Large B-Cell Lymphoma Using Gene Expression and Proteomic Data

Huiqing Liu, PhD, Jin Lu, PhD, Zhiwan Dong, PhD, Hao Liu, PhD, Edward Salinas, MSc, Sherry Owens, PhD, Michael A. Pratta, MSc, Michael F. Smith, PhD, Hiroomi Tada, MD PhD, Robert C Newton, PhD, Timothy Burn, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1712.
https://doi.org/10.1182/blood-2018-99-116949
Published: 2018
Journal Articles

LSD1 Inhibition Induces Fetal Hemoglobin Expression and Provides a Novel Therapeutic Approach to Sickle Cell Disease

Sang Hyun Lee, PhD, Maxim Soloviev, MDPhD, Yan Zhang, PhD, Valerie Roman, Gengjie Yang, Kevin Bowman, Krista Burke, Alexander Margulis, Sybil O'Connor, Yan-ou Yang, PhD, Liangxing Wu, PhD, Richard Wynn, PhD, Timothy Burn, PhD, Dana Shuey, PhD, Sharon Diamond, PhD, Wenqing Yao, PhD, Gregory Hollis, PhD, Swamy Yeleswaram, PhD, Alan Roberts, PhD, Reid Huber, PhD, Peggy Scherle, PhD, Bruce Ruggeri, PhD
Journal: Blood
Blood (2016) 128 (22): 2472.
https://doi.org/10.1182/blood.V128.22.2472.2472
Published: 2016
Journal Articles

Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)

Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Haifa Kathrin Al-Ali, MD, Giovanni Barosi, MD, Claire N Harrison, DM FRCP FRCPath, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Matthew Squires, PhD, Timothy Burn, PhD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, Tiziano Barbui, MD, Heinz Gisslinger, MD, Jean-Jacques Kiladjian, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 802.
https://doi.org/10.1182/blood.V120.21.802.802
Published: 2012
Journal Articles

Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,

Paola Guglielmelli, MD, PhD, Lisa Pieri, MD, Enrico Tagliarico, MD, Roberta Zini, BiSci, Ruggiero Norfo, PhD, Alberto Bosi, Kris Vaddi, PhD, DVM, Timothy Burn, PhD, Nancy Contel, Srdan Verstovsek, MD, PhD, Rossella Manfredini, BiSci, PhD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2011) 118 (21): 3852.
https://doi.org/10.1182/blood.V118.21.3852.3852
Published: 2011
Journal Articles

Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F:WT JAK2 Ratio in Patients with High Allele Burdens despite Profound Clinical Improvement Following Treatment with the JAK Inhibitor, INCB018424

Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Animesh D. Pardanani, MBBS, PhD, Timothy Burn, PhD, Kris Vaddi, PhD, DVM, John Redman, MD, Edward C Bradley, MD, Richard Levy, MD, Steven Friedman, MD, Gregory Hollis, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2008) 112 (11): 2802.
https://doi.org/10.1182/blood.V112.11.2802.2802
Published: 2008
Journal Articles

The Clinical Phenotype of Myelofibrosis Encompasses a Chronic Inflammatory State That Is Favorably Altered by INCB018424, a Selective Inhibitor of JAK1/2

Ayalew Tefferi, MD, Hagop M Kantarjian, Animesh D. Pardanani, MBBS, PhD, Ruben A. Mesa, MD, FACP, Robert C Newton, PhD, Peggy A Scherle, PhD, Timothy Burn, PhD, Srdan Verstovsek
Journal: Blood
Blood (2008) 112 (11): 2804.
https://doi.org/10.1182/blood.V112.11.2804.2804
Published: 2008
Journal Articles

Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Jordan Fridman, PhD, Roberto Nussenzveig, PhD, Phillip Liu, PhD, James Rodgers, PhD, Timothy Burn, PhD, Patrick Haley, DVM, Peggy Scherle, PhD, Robert Newton, PhD, Gregory Hollis, PhD, Steven Friedman, MD, Srdan Verstovsek, MD, PhD, Kris Vaddi, PhD
Journal: Blood
Blood (2007) 110 (11): 3538.
https://doi.org/10.1182/blood.V110.11.3538.3538
Published: 2007